In the eNRGy trial conducted by Schram et al., a cohort of 18 patients with pancreatic cancer received treatment with zenocutuzumab (MCLA-128), resulting in an ORR of 39% (34% ORR in NRG1+ tumors) [96]. This evidence concerns the gene NRG1 and pancreatic neoplasm.